Zealand Pharma Shares Sink 25% After Trial Results
Zealand Pharma shares tumbled in Copenhagen on Monday. The drop followed investor worries over side effects tied to Boehringer Ingelheim’s survodutide, which offset hope around the drug's fat-loss results. Zealand’s investor page listed the shares at 241.40 Danish crowns, off 26.02%. Reuters said the stock led declines on Europe’s STOXX 600 early in the session.
